Abstract
No public abstract is available from the verified source records.
John G.F. Cleland, Stephen John Greene, D J Van Veldhuisen, Johann Bauersachs
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · 2021
Heart failure drug treatment: the fantastic four
10.1093/eurheartj/ehaa1012 · 2021
2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehad195 · 2023
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
10.1016/s0140-6736(22)02076-1 · 2022
A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction
10.1002/ehf2.14197 · 2023
Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy
10.1093/eurheartj/ehaf244 · 2025
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
10.1002/ejhf.3295 · 2024
From prescription to persistence: guideline-recommended medical therapy in heart failure with reduced ejection fraction
10.1093/eurheartj/ehag198 · 2026
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3/3
10.1016/j.jacc.2023.04.057 · 2023
The year in cardiovascular medicine 2025: the top 10 papers in heart failure
10.1093/eurheartj/ehaf1044 · 2026
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial
10.1016/s0140-6736(25)01665-4 · 2025
Digitoxin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa2415471 · 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
10.1093/eurheartj/ehaf655 · 2026
Digitalis—back on centre stage for HFrEF
10.1093/ejhf/xuaf002 · 2026
Beyond the 4 pillars: where does vericiguat stand in contemporary HFrEF care?
10.1016/j.jacc.2025.10.040 · 2025
No additional external references are available.